NTU Finds GLP-1 Drugs Slash Cancer Risk
A multinational research team led by National Taiwan University (NTU) Hospital recently achieved a significant breakthrough, publishing their findings in the top-tier oncology journal Annals of Oncology. The study reveals that non-diabetic obese adults using GLP-1 receptor agonists—commonly known as weight-loss injections like Semaglutide and Tirzepatide—experience a remarkable 41% reduction in the risk of developing obesity-associated cancers (OACs) compared to those receiving only diet and exercise counseling.
(7 September, 2026, Global Education News)